First-in-class p300/CBP inhibitor to treat specific cancers

CellCentric is a UK based biotechnology company focused on the development of the novel drug CCS1477 for specific cancers.

The company’s leadership has deep R&D experience gained in academia, large pharma and biotechs, spanning from basic biological research through to international clinical development programmes.

Over time the company has investigated a wide range of epigenetic-related pathways to address disease. More than 50 potential drug targets have been investigated, before focussing on p300/CBP. The selection was driven by strong biological understanding, a clear path for developing selective and potent small-molecule inhibitor drugs, as well as well-defined relevance and targeted application to treat cancer.

Find out more about CellCentric on their website.